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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYUsing a viral model of the demyelinating disease multiple sclerosis (MS), we show that intraspinal transplantation of human embryonic
stem cell-derived neural precursor cells (hNPCs) results in sustained clinical recovery, although hNPCs were not detectable beyond day 8
posttransplantation. Improved motor skills were associated with a reduction in neuroinflammation, decreased demyelination, and
enhanced remyelination. Evidence indicates that the reduced neuroinflammation is correlated with an increased number of
CD4+CD25+FOXP3+ regulatory T cells (Tregs) within the spinal cords. Coculture of hNPCs with activated T cells resulted in reduced
T cell proliferation and increased Treg numbers. The hNPCs acted, in part, through secretion of TGF-b1 and TGF-b2. These findings indi-
cate that the transient presence of hNPCs transplanted in an animalmodel ofMS has powerful immunomodulatory effects andmediates
recovery. Further investigation of the restorative effects of hNPC transplantation may aid in the development of clinically relevant MS
treatments.INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system (CNS) involving immune
cell infiltration into the central nervous system (CNS),
which results in demyelination and axonal loss that
culminates in extensive neurological disability (Steinman,
1996). The demyelination is progressive over time;
however, spontaneous, but transient, myelin repair can
occur during the course of the disease. Endogenous oligo-
dendrocyte precursor cells (OPCs) are believed to be
responsible for spontaneous remyelination (Lassmann
et al., 1997), but it is unclear why these cells only act
intermittently. An important unmet clinical need for MS
patients is an effective method to induce sustained
remyelination.
Cell transplantation therapy is a promising approach to
promote remyelination in MS patients; human embryonic
stem cells (hESCs) and induced pluripotent stem cells, as
well as fetal brain, are potential sources of therapeutic cells
(Bru¨stle et al., 1999; Mu¨ller et al., 2006). Studies in animal
models have demonstrated the benefits of cell therapy in
treating mouse models of MS. For example, myelin genera-
tion (Buchet et al., 2011), accompanied by modulation of
inflammatory responses, followed CNS transplantation ofStehuman neural precursor cells into animal models in
which myelin formation is defective or demyelination is
induced via immunization with encephalitogenic pep-
tides. Another model, which we employed in this study,
is based on findings that persistent infection with a mouse
neurotropic coronavirus correlates with chronic neuroin-
flammation and immune-mediated demyelination (Lane
and Buchmeier, 1997).
Here, we demonstrate sustained neurologic recovery
out to 6 months following intraspinal transplantation
of hESC-derived NPCs (hNPCs) into mice in which
inflammatory-mediated demyelination was initiated
by persistent viral infection of the CNS. We observed
clinical recovery associated with muted neuroin-
flammation and decreased demyelination, along with
emergence of CD4+CD25+FOXP3+ regulatory T cells
(Tregs). Ablation of Tregs in hNPC-transplanted mice
inhibited the improvement in motor skills and increased
neuroinflammation and in vitro, hNPCs modulated
cytokine secretion and proliferation by antigen-sen-
sitized T cells. Interestingly, the hNPCs were rapidly
rejected after transplantation into these immunocom-
petent mice, indicating that the sustained neurologic re-
covery was not dependent on stable engraftment of
hNPCs.m Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authors 825
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hNPCs Enhance Clinical Recovery of MS Model MiceRESULTS
Intraspinal Injection of Human ESC-Derived Neural
Precursor Cells Results in Clinical Improvement of
JHMV-Infected Mice
Human neural precursor cells (hNPCs) were derived from
WA09 hESCs using modifications of published protocols
(Trosset et al., 2006; Vogt et al., 2011). An important modi-
ficationwas cell passaging to control cell density during the
9-day-directed differentiation protocol, and the trans-
planted cells had a uniform cellular morphology (Fig-
ure 1A). Because there is considerable phenotypic diversity
among preparations of neural precursor cells (Mu¨ller et al.,
2008), we performed extensive microarray-based transcrip-
tome analysis to define a genomic phenotype for the cells
that showed clinical activity. The microarray analysis
revealed a consistent profile of gene expression among
separate populations of hNPCs differentiated by our
method (Figure 1B; Table S1 available online).
To evaluate the effects of hNPCs in promoting clinical
recovery, we injected cells into the spinal cords of immuno-
competent mice with established JHMV-induced clinical
disease (Carbajal et al., 2010), which was generated by
the injection of susceptible mice with the neurotropic
JHM strain of mouse hepatitis virus (JHMV); consistent
with previous studies, the mice showed viral persistence
in white matter tracts and hind-limb paralysis, as well as
demyelination and neuroinflammation (Templeton and
Perlman, 2007).
Injection of hESC-derived hNPCs, but not human fibro-
blasts, resulted in a reduction in the severity of clinical
disease and improved motor skills (Figure 1C) that were
sustained out to 6 months posttransplantation (pt) (Fig-
ure 1D). Of 96 mice injected with hNPCs, 66 (73%)
displayed a significant (p < 0.05) improvement in motor
skill recovery, whereas nine of the 63 mice (14%) trans-
planted with the vehicle control improved. Living cells
and intraspinal injection were necessary for the clinical
recovery; transplantation of dead cells or delivery of cells
via intravenous or intraperitoneal injection did not result
in improved clinical outcome (data not shown).
Because transplantation of the hNPCs was performed in
immunocompetent mice, we expected the cells to be
rapidly rejected. To track the fate of the cells following
injection, we transplanted hNPCs constitutively express-
ing the Photinus pyralis luciferase gene andmonitored their
presence by daily luciferin injection and IVIS imaging.
Luciferase signals within the spinal cord were highest at
day 1 pt and declined below the level of detection by day
8 pt. (Figure 1E). Imaging of transplanted cells revealed
that the hNPCs did not migrate extensively within the
spinal cord and did not disseminate into peripheral tissues.
To confirm the imaging data, spinal cords from hNPC-826 Stem Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authortransplanted mice were removed at defined times pt,
serially sectioned 5 mm rostral and 5 mm caudal to the
injection site, and immunostained for a human-specific
cytoplasmic antigen (Uchida et al., 2012). As shown in
Figure 1F, hNPCs were detected at days 1 and 4 pt, but
staining was very weak by day 7 pt. These findings confirm
that transplanted hNPCs survived for approximately
1 week after transplantation.
Neuroinflammation and Demyelination Was Reduced
in hNPC-Transplanted Mice
To investigate potential mechanisms underlying hNPC-
mediated improvement in neurologic function, we
examined neuroinflammation in hNPC-transplanted
mice. Analysis of spinal cords from hNPC-transplanted
mice at 21 days pt revealed a marked reduction in inflam-
matory cells present within spinal cords compared to the
controls. Clinical recovery following hNPC transplanta-
tion is associated with reduced neuroinflammation in the
spinal cord (Figure 2A). Immunostaining for activated
macrophage/microglia and T cells (Figures 2B and 2C),
critical in amplifying the severity of demyelination in
JHMV-infected mice, revealed an overall reduction in
immunoreactive cells within the spinal cords that was
sustained past 175 days pt. (data not shown). Quantifica-
tion of macrophage/microglia and T cell immunostaining
indicated that hNPC transplantation resulted in a signifi-
cant (p < 0.01) reduction in both cell populations
compared to control mice (Figure 2D). Flow cytometry
analysis confirmed immunostaining by showing reduced
infiltration of CD4+ and CD8+ T cells into the CNS of
hNPC-treated mice compared to controls (Figures 3A and
3B). Accumulation of virus-specific CD4+ and CD8+
T cells in the CNS of hNPC-treated mice was also deter-
mined by tetramer staining (Zhao et al., 2011). Infiltration
of CD4+ T cells recognizing the immunodominant epitope
within the viral matrix (M) glycoprotein spanning amino
acids 133–147 (M133–147) and CD8+ T cells specific for
the immunodominant epitope in the spike glycoprotein
located on amino acids 510–518 (S510–518) were both
reduced in hNPC-transplanted mice (Figures 3A and 3B).
In addition, macrophage (F4/80+CD45high) infiltration
was reduced in hNPC-transplanted mice (Figure 3C). Anal-
ysis of viral titers within the CNS of experimental mice
indicated that control of viral replication within the spinal
cords was not affected by hNPC transplantation; repli-
cating virus was not detected (Figure 3D), and there were
no differences in transcript levels of viral RNA (Figure 3E).
Spinal cord sections from transplanted mice that
displayed improved motor function showed a dramatic
reduction in the severity of demyelination when compared
to control mice (Figure 4A). Quantification of demyelin-
ation indicated a significant (p < 0.05) reduction in whites
Figure 1. Characteristics and Transplantation of hESC-Derived NPCs into JHMV-Infected Mice
(A) Human neural precursor cells (hNPCs) after 9 days of directed differentiation. The cells are closely packed and have a distinctive
morphology, and the culture appears to be homogeneous.
(B) Gene expression signature of hNPCs used for transplantation experiments. A heatmap shows the hierarchical clustering of 118 probes
that were significantly differentially expressed (p < 0.001) in hNPCs. Five independent cultures of hNPCs were compared by global gene
expression analysis (Human HT-12 v. 4 Expression Beadchip), with four samples of human pluripotent stem cells (two hESC and two iPSC
lines) and a sample of human fibroblasts. The scale at right indicates the fold differences in gene expression, with yellow indicating
relatively higher expression and blue indicating relatively lower expression.
(C) Human fibroblasts or hNPCs were transplanted by intraspinal injection into JHMV-infected mice at day 14 postinfection. hNPC-
transplanted mice improved (p < 0.05) motor skills compared to animals transplanted with either fibroblasts or vehicle alone (control).
(D) Improved (p < 0.05) clinical recovery in hNPC-transplanted JHMV-infected mice was sustained out to 168 days posttransplantation (pt)
when compared to infected mice treated with vehicle alone. For experiments shown in (C) and (D), the data are the results of two in-
dependent experiments with data shown as averages ± SEM.
(E) Daily IVIS imaging of luciferase-labeled hNPCs revealed that following intraspinal transplantation, cells were reduced to below the level
of detection by day 8 posttransplantation; representative mice are shown. IVIS imaging was performed on vehicle-transplanted mice as a
control.
(F) Representative immunohistochemical staining for human cells (STEM121 antibody) at defined times pt confirms IVIS imaging data
and shows that following intraspinal transplantation, hNPCs are gradually eliminated, with very few cells remaining by day 7 post-
transplant; 603 images are of framed areas in the 43 images.
Stem Cell Reports
hNPCs Enhance Clinical Recovery of MS Model Micematter damage in mice treated with hNPCs (1.9 ± 0.4,
n = 9) compared to control mice (3.1 ± 0.1, n = 7) (Fig-
ure 4B). EM analysis of spinal cord sections was performedSteto determine whether remyelination was occurring in
hNPC-transplanted mice. Assessment of the g-ratio, the
ratio of the inner axonal diameter to the total outer fiberm Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authors 827
Figure 2. hNPC-Mediated Clinical Recov-
ery Is Associated with Dampened Neuro-
inflammation at Day 21 Pt
(A) Clinical recovery following hNPC trans-
plantation was associated with reduced
neuroinflammation indicated by H&E
staining of spinal cord sections (upper
panel, control; lower panel, hNPC-treated).
(B and C) Immunohistochemical staining
demonstrated reduced (B; upper panel,
control; lower panel, hNPC-treated) macro-
phage infiltration/microglia activation
(IBA-1 reactivity, brown) and (C) CD3-pos-
itive lymphocytes (pan-T cell marker, Alexa
488/green staining) within spinal cords of
hNPC-treated and control mice (upper
panel, control; lower panel, hNPC-treated).
(D) Quantification of IBA-1 and CD3-reac-
tive cells indicated a significant reduction
in macrophage/microglia and CD3-positive
cells following hNPC transplantation
compared to control mice. Data are repre-
sentative of at least two independent ex-
periments with a minimum of three mice per
group; data are presented as averages ±
SEM. Mann-Whitney t tests were used to
determine the p values.
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hNPCs Enhance Clinical Recovery of MS Model Micediameter, is a structural index of remyelination; lower
ratios indicate more extensive myelination (Liu et al.,
2001; Moore et al., 2013). The calculated g-ratio of hNPC-
transplanted mice (0.83 ± 0.005, n = 533 axons) was signif-
icantly (p < 0.001) lower than that of control mice (0.94 ±
0.005, n = 541 axons) at 3 weeks pt (Figure 4C), indicating a
greater degree of myelination in the transplanted mice.
hNPC Treatment Increased the Frequency of
CD4+CD25+FOXP3+ Treg Cells within the CNS
Tregs have been shown to dampen neuroinflammation
within the CNS of JHMV-infected mice (Trandem et al.,
2010). In our studies, hNPC-mediated clinical recovery
was associated with muted CNS inflammation, suggesting
that the transplanted hNPCs may have promoted recovery
through Treg-mediated mechanisms. Flow analysis of
dissociated cells from spinal cords revealed an increased
frequency of Tregs (CD4+CD25+FOXP3+) in the spinal
cords of hNPC-transplanted mice at day 10 pt (Figures 5A
and 5B). In order to clarify the role of Tregs in improved
clinical recovery, hNPCs transplanted mice were treated
at days 2, 0, and +2 pt with anti-CD25 monoclonal anti-828 Stem Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authorbody, which efficiently blocks Treg activity (Kohm et al.,
2006). Flow analysis of CD4+CD25+FOXP3+ T cells within
draining cervical lymph nodes of anti-CD25-treated
mice at day 9 pt confirmed efficient depletion of Tregs
(>95%) (data not shown). This treatment inhibited func-
tional improvement in hNPC-transplanted mice out to
day 20 pt (Figure 5C). Further, the anti-CD25 treatment
was associated with increased neuroinflammation in
hNPC-transplanted animals when compared to trans-
planted animals treated with control antibody (Figures
5D and 5E).
We determined whether hNPCs influenced cytokine
expression and proliferation of activated T cells; previous
studies reported that transplanted hNPCs could modulate
T-cell-mediated cytokine secretion (Liu et al., 2013), and
secretion of proinflammatory cytokines, including IFN-g
and TNF-a, has been suggested to contribute to the severity
of demyelination (Pewe and Perlman, 2002; Sun et al.,
1995). Stimulation of T cells isolated from hNPC-trans-
planted mice with virus-specific CD4+ peptide resulted
in reduced (p < 0.05) expression of proinflammatory
cytokines IFN-g and TNF-a, whereas expression ofs
Figure 3. hNPC Transplantation Restricts
T Cell and Macrophage Infiltration into
the CNS
(A–C) Spinal cords from hNPC-treated and
control mice were removed at 3 weeks pt,
and infiltrating cells were immuno-
phenotyped by flow staining for defined
surface antigens (A) Infiltration of total
CD4+ T cells and virus-specific CD4+ cells was
reduced in hNPC-treated mice compared to
controls. In addition, infiltration of CD8+
cells and virus-specific CD8+ T cells (B) was
also reduced in hNPC-transplanted animals
compared to controls. (C) Macrophage (F4/
80+CD45high) accumulation in spinal cords
was reduced in hNPC-transplanted mice
compared to control mice. Representative
flow dot blots are shown in (A), (B), and
(C). Bar graphs are representative of at least
two independent experiments with a mini-
mum of four mice per experimental group;
data are presented as averages ± SEM.
Paired t tests were used to determine the
p values.
(D and E) hNPC-mediated clinical recovery
was not associated with increased spinal
cord viral burden as determined by plaque
assay (D) and quantitative PCR analysis of
viral RNA (E). For results in (D) and (E), data
are representative of at least two indepen-
dent experiments with a minimum of three
mice per experimental group. Data in (E)
represent averages ± SEM. Mann-Whitney
t tests were used to determine the p values.
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to control mice (Figure 6A). We determined whether the
hNPC-induced protective effect was mediated by suppres-
sion of virus-specific T cell proliferation, as this could
contribute to clinical recovery. Coculture of hNPCs with
splenocytes obtained from JHMV-immunized mice and
pulsed with the CD4+ T-cell-specific immunodominant
epitope M133–147 peptide resulted in a dose-dependent
suppression of proliferation of CD4+ T cells (Figure 6B)
that was associated with an increased frequency of
CD4+CD25+FOXP3+ T cells (Figure 6C). Further character-
ization revealed that proliferation of virus-specific M133–
147 CD4+ T cells (Figure 6D), but not virus-specific S510–
518 CD8+ T cells (Figure 6E), was lower (p < 0.001) when
compared to control cultures in which hNPCs were not
included.SteTGF-b Signaling Was Required for the Anti-
inflammatory Effect of Transplanted hNPCs
Our transplantation results indicated that the short-term
presence of transplanted hNPCs resulted in long-term
clinical recovery and decreased neuroinflammation and
demyelination. This suggests that transplanted hNPCs
may secrete factors that have long-term effects on neuroin-
flammationanddemyelination. Recent studieshave shown
that certain hNPCs secrete the immunomodulatory cyto-
kines TGF-b1 and TGF-b2 and there is an increase in the fre-
quency of CD4+CD25+FOXP3+ T cells following coculture
of hNPCs with human PBMCs (Liu et al., 2013). Ourmicro-
array gene expression analysis identified TGF-b2 among the
genes that were consistently more highly expressed in
hNPCs compared to other cell types (Table S1). We used
qRT-PCR to compare transcript levels in hESCs and hNPCsm Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authors 829
A B
C
Figure 4. hNPC Treatment Reduced the
Severity of Demyelination
(A) Representative luxol fast blue stain of
spinal cord sections obtained from either
hNPC-treated or control mice at 3 weeks pt.
Dashed lines indicate areas of white matter
damage.
(B) Quantification of the severity of demy-
elination at 3 weeks posttransplant in-
dicates that white matter damage is signif-
icantly decreased (p < 0.05) in hNPC-treated
versus control.
(C) Representative EM images (12003)
showing increased numbers of remyelinated
axons (red arrows) compared to demyeli-
nated axons (blue arrows) in hNPC-trans-
planted mice compared to control mice.
Calculation of g-ratio, as a measurement of
structural and functional axonal remyelina-
tion, revealed a significantly (p < 0.001)
lower g-ratio (indicative of remyelination)
in hNPC-treated mice (0.83 ± 0.005, n = 533 axons) compared to control mice (0.94 ± 0.005, n = 541 axons) at 3 weeks pt. For graphs
shown in (B) and (C), data are representative of at least two independent experiments with a minimum of three mice per group; data are
presented as average ± SEM; the Mann-Whitney t test was used to determine the p values.
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tially expressed (p < 1 3 106) in the hNPCs (Figure 7A).
TGF-b2 transcripts were 250-fold higher in hNPCs, whereas
TGF-b1 transcripts were5-fold higher compared to hESCs
(Figure 7A).Hepatocyte growth factor (HGF)was previously
shown to be associated with mesenchymal stem cell-medi-
ated recovery in an experimental autoimmune encephalo-
myelitis (EAE)mousemodel (Bai et al., 2012), but our results
showed that HGF transcripts were nearly undetectable in
our hNPCs (Figure 7A). Consistent with the transcript anal-
ysis, measurement of protein levels in culture medium
conditioned by hNPCs showed that there was an approxi-
mate40-foldhigher level of TGF-b2anda3-foldhigher level
of TGF-b1 in hNPC-conditioned medium (CM) compared
to control medium (Figure 7B). Inclusion of neutralizing
antibodies specific for TGF-b1 or TGF-b2 blocked the ability
of hNPCs to inhibit proliferation of virus-specific CD4+
T cells, and inclusion of both antibodies had the largest
effect (Figure 7C). In addition, antibody targeting of TGF-
b1 or TGF-b2, alone or in combination, reduced numbers
of CD4+CD25+FOXP3+ T cells emerging in cocultures of
hNPCs and T cells (Figure 7D), suggesting an important
role for these cytokines in contributing to the immuno-
modulatory effects of hNPCs.DISCUSSION
There has been growing interest in the use of cell transplan-
tation as therapy for neurological diseases since the first830 Stem Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authorhuman trials using fetal neural precursors for Parkinson’s
disease were performed more than 20 years ago (reviewed
in Barker et al., 2013). Currently, there are preclinical
studies and clinical trials using fibroblastic adult mesen-
chymal stem cells (reviewed in Neirinckx et al., 2013) and
fetal-derived neural cells (Uchida et al., 2012) for transplan-
tation to treat neurological disease. A recent clinical study
showed that fetal neural cell transplants promoted myeli-
nation in individuals afflicted with Pelizaeus-Merzbacher
disease (PMD), a rare hypomyelinating disease (Gupta
et al., 2012).
Multiple sclerosis (MS) is a demyelinating disease that is
an attractive target for cell therapy because of the lack of
long-term therapeutic benefit from current treatments.
We investigated a cell-therapy strategy using humanneural
precursor cells derived from hESCs for their therapeutic
potential in a mouse model of demyelination induced by
viral infection. Available evidence indicates that the cause
of MS is multifactorial and includes genetic background
and environmental influences (Goodin, 2012; Pugliatti
et al., 2008). Although no clear causal relationship between
MS and viral infection has been firmly established, viruses
are capable of persisting within the CNS and have been
implicated in initiating or exacerbating MS symptoms
(Gazouli et al., 2008).
We found that hNPC-mediated recovery in our model
was associated with amarked reduction in neuroinflamma-
tion, characterized by reduced infiltration of inflammatory
T cells and macrophages within the spinal cords and emer-
gence of regulatory T cells (Tregs). Importantly, recoverys
Figure 5. hNPC-Mediated Recovery Is
Associated with Treg Emergence within
the Spinal Cord
(A–E) Mice were infected intracranially with
JMHV and transplanted with either hNPCs or
vehicle alone at day 14 post-infection.(A)
Examination of Tregs within the spinal
cords by flow analysis (CD4+CD25+FOXP3+)
revealed an increased frequency of Tregs in
hNPC-transplanted animals at day 10 post-
transplantation, a time at which animals
began to display improved motor skills
compared to control mice. A representative
flow cytometric dot blot is shown. (B)
Quantification of Treg numbers in spinal
cords of mice indicated a significant (p <
0.05) increase in the number of Tregs in
hNPC-transplanted mice versus controls
from 8–10 days posttransplantation. Data
are representative of three independent
experiments with a minimum of three mice
per group; data are presented as average ±
SEM. Mann-Whitney t tests were used to
determine the p values. (C) hNPC-trans-
planted mice receiving anti-CD25 antibody
did not display recovery in motor skills as
compared to hNPC-treated mice treated
with control antibody. (D and E) H&E
staining of spinal cords of hNPC-treated
mice treated with either control antibody
(D) or anti-CD25 (E) indicates that deple-
tion of Tregs increases neuroinflammation
within white matter tracts (representative
images are shown).
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in these immunocompetent mice. In MS, as in other
neurodegenerative diseases, there is growing evidence
that long-term survival of transplanted cells is not required
for beneficial effects. A recent study (Bai et al., 2012)
reported that mesenchymal stem-cell-induced recovery in
the EAE mouse model and in lysolecithin-induced demye-
lination was dependent upon release of HGF. Although
we have found that our hNPCs do not produce detectable
HGF mRNA or protein, our findings are similar with regard
to immunomodulation, diminished spread of demye-
lination, and remyelination. Additional studies also sup-
port the immunomodulatory properties associated with
transplanted stem cells; in one study, intracerebroventri-
cularly injected human glial cells rapidly died yet resulted
in reduction of the clinical severity of EAE that correlated
with inhibited proliferation of myelin-specific T cells
(Kim et al., 2012b). Similarly, human ESC-derived oligo-
dendrocyte precursors did not survive past 8 days
following intraventricular injection into mice with EAE,Steyet animals displayed decreased neurologic disability, and
this was associated with increased numbers of regulatory
T cells within the CNS (Kim et al., 2012a). These reports
are consistent with growing evidence that transplanted
stem cells rarely differentiate into cells of neural lineage,
and their efficacy often appears to be through delivery of
trophic factors (Blurton-Jones et al., 2009; Mu¨ller et al.,
2006) or by modulating inflammation (Neirinckx et al.,
2013).
An important question that remains an area of ongoing
work is to determine whether the sustained presence of
Tregs after hNPC rejection continues to dampen neuro-
inflammation long term.Webelieve this is possible because
hNPCs had already disappeared from the spinal cord at the
time we detected increased numbers of Tregs. Our results
suggest that Tregs are a critical component of the recovery,
because antibody-mediated ablation of Tregs reduced the
clinical effects of hNPCs. We are interested in character-
izing cytokine profiles within both the CNS and draining
cervical lymph nodes, as recent studies argue thatm Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authors 831
Figure 6. hNPCs Modulate T Cell
Responses
(A) T cells were isolated from draining
cervical lymph nodes of control and hNPC-
transplanted mice at 3 weeks pt, stimulated
with M133–144 viral peptide, and their
secretion of IFN-g, TNF-a, and IL-10 was
determined by ELISA after 48 hr of culture.
IFN-g and TNF-a secretion was lower and
IL-10 secretion higher in hNPC-treated
mice.
(B) hNPCs were cocultured with activated
T cells at the indicated ratios, and T cell
proliferation was determined by eFluor 670
staining. Results demonstrated that hNPCs
suppressed T cell proliferation in a dose-
dependent manner.
(C) Coculture of hNPCs with activated T cells
either in the presence or absence of the
immunodominant CD4 viral peptide (M133–
147) revealed increased numbers of CD4+
CD25+FOXP3+ T cells when viral peptide was
included.
(D) Coculture with hNPCs inhibited prolif-
eration (p < 0.001) of M133–147 CD4+
T cells.
(E) S510–518-specific CD8+ T cells were not
affected following coculture with hNPCs.
Data are representative of at least two in-
dependent experiments with a minimum of
three mice per group; data are presented as
average ± SEM. Mann-Whitney t tests were
used to determine the p values in (A) and
(B); paired t tests were used to determine
the p values in (C) to (E).
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and demyelination in JHMV-infected mice occurs in
lymphatic tissue (Trandem et al., 2010) and that certain
cytokines can function in controlling Treg suppression
(Zhao et al., 2011). As it is unlikely that transplanted
hNPCswere differentiating into oligodendroglia, it appears
that remyelination is occurring in response to activation
of endogenous OPCs through mechanisms that remain to
be defined. One possible mechanism is that the trans-
planted cells or Tregs, or both, may secrete factors that in-
fluence maturation of OPCs.
Our studies suggest that direct delivery of precursor cells
into the CNS via intraspinal transplantation influences
clinical and histologic outcome through interactions of
transplanted cells with inflammatory cells present within
the CNSmicroenvironment, such as by affecting the emer-
gence of Tregs. This suggests that transplanted hNPCs can832 Stem Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authormanipulate the microenvironment, presumably through
localized secretion of soluble factors that modulate the
immune response and remyelination. Our work and the
work of others (Liu et al., 2013) shows that cultured hNPCs
secrete anti-inflammatory cytokines, including TGF-b1 and
TGF-b2. Based on our experiments and previous reports,
our current hypothesis is that the emergence of Tregs in
the areas of the transplant may be due to localized expres-
sion of TGF-b1 and/or TGF-b2 following hNPC transplanta-
tion. The immunodulatory effects of TGF-b in regulating
immune tolerance and T cell homeostasis are well docu-
mented (Sakaguchi, 2004), and our findings indicate an
important role for TGF-b1 and TGF-b2 in contributing to
the hNPC-mediated inhibition of proliferation of anti-
gen-specific T cells and in increasing the frequency of
regulatory T cells. This evidence supports the idea that
the presence of transplanted hNPCs suppresses thes
Figure 7. TGF-b Secretion and T Cell Responses
(A) RNA was extracted from hNPCs at day 9 of neural differentiation, and qRT-PCR was used to determine relative transcript levels of TGF-b1,
TGF-b2, and HGF. Values were normalized to internal GAPDH levels and are shown as fold differences compared to undifferentiated hESC
expression levels using DDCt calculations; data are presented as averages ± SEM.
(B) ELISA determination of TGF-b1 and TGF-b2 in culture medium conditioned by hNPCs compared to unconditioned medium; data are
presented as average ± SEM and representative of three independent experiments.
(C) In hNPC-T cell cocultures, inclusion of anti-TGF-b1 or anti-TGF-b2 alone or in combination impaired the ability of hNPCs to block
proliferation of virus-specific CD4+ T cells.
(D) Antibody targeting of TGF-b1 or TGF-b2 reduced the numbers of CD4+CD25+ FOXP3+ Tregs. (C) and (D) contain data of a minimum of four
mice per group; mean values are presented; error bars represent SEM. Mann-Whitney t tests were used to determine the p values in (A) and
(B); paired t tests were used to determine the p values for (C) and (D); * p < 0.05, ** p < 0.01, *** p < 0.001.
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of proinflammatory cytokines IFN-g and TNF-a, while
enhancing the increase in T regulatory cells that coincides
with clinical recovery.
In summary, we demonstrate that transplantation of
hNPCs into amousemodel of viral-induced demyelination
results in prolonged clinical recovery up to at least
6 months in spite of the disappearance of transplanted
hNPCs after only a week. Importantly, we found that the
methods used to prepare the hNPCs are critical to their
functional phenotype. Human neural precursor cells are
notably diverse (Mu¨ller et al., 2008), and culture methods
(Chetty et al., 2013; Nazareth et al., 2013) have profound
effects on cellular differentiation. To facilitate furtherSteinvestigation of the cells and the mechanisms underlying
hNPC-mediated recovery, we generated a genomic pheno-
type of the cells that can serve as a guide to define the
precise cell type used in our studies.
Our findings extend the existing evidence that long-term
engraftment is not important for sustained clinical and
histologic recovery. Our evidence points to secreted factors
produced by the hNPCs in the local environment as the
regulators of T cell fate and remyelination activity by
endogenous OPCs. Because they are produced by the
hNPCs used in our study and have known effects on
T cell development, members of the TGF-b family are
strong candidates as triggers initiating clinical recovery.
Our further studies will focus on identification andm Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The Authors 833
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the restorative effects of transplanted hNPCs, which may
guide further development of stem cell and perhaps cell-
free therapies for MS.EXPERIMENTAL PROCEDURES
Animals and Virus
Age-matched (5–7 weeks) C57BL/6 (H-2b, National Cancer
Institute [NCI]) were infected intracranially (ic) with 150 plaque-
forming units (pfu) of MHV strain J2.2v-1 (JHMV) in 30 ml sterile
Hank’s balanced salt solution (Carbajal et al., 2010). Mice were
sacrificed at various time points following hNPC transplantation,
and tissues were removed and processed for analysis. All experi-
ments were approved by the University of California, Irvine Insti-
tutional Animal Care and Use Committee protocols #1998-2022
and 2010-2943. Determination of viral titers from the CNS of
infected mice was performed by isolating tissues at defined times
after infection, homogenizing tissue, and overlaying clarified
supernatant on the DBT astrocytoma cell line as previously
described (Liu et al., 2001). For methods describing quantification
of viral RNA in CNS tissues, please see the Supplemental Experi-
mental Procedures.Generation of hNPCs
Feeder-free-adapted WA09 hESCs were seeded at a concentration
of 1.0 3 104 cells per cm2 in BD Matrigel Basement Membrane
Matrix (BD Bioscience) on coated six-well plates and cultured
for 24 hr in human embryonic stem cell culture medium
(STEMPRO hESC SFM; Life Technologies). The medium was
then replacedwithNPCdifferentiationmedium (Dulbecco’smodi-
fied Eagle’s medium [DMEM]/F12, 20% Knockout Serum Replace-
ment [KSR] [Life Technologies], 13 nonessential amino acids
[NEAA; Life Technologies], 13 GlutaMAX [Life Technologies],
and 0.1 mM 2-mercaptoethanol [Life Technologies]) supple-
mented with 20 ng/ml of midkine (MK; Millipore), and small
molecules: 2 mM each of dorsomorphin (6-[4-(2-Piperidin-1-yle-
thoxy) phenyl]-3-pyridin-4-ylpyrazolo [1,5-a] pyrimidine; Sigma),
A 83-01 (3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-
pyrazole-1-carbothioamide; Tocris), and PNU-74654 (benzoic
acid, 2-phenoxy-, 2-[(5-methyl-2-furanyl)methylene] hydrazide;
Sigma). Medium was changed daily. The cells were split 1:3 on
days 3 and 6 using Accutase (Life Technologies). hNPCs were
harvested for transplantation 9 days after the start of the differen-
tiation protocol. For methods describing gene expression arrays
and generation of LUC+ cells, please see the Supplemental Experi-
mental Procedures.hNPC Transplantation
For transplantation studies, JHMV-infectedmice received an injec-
tion of either 2.53 105 hNPCs or human fibroblasts (suspended in
2.5 ml DMEM/F12) at T9 of the spinal cord on day 14 pi. Control
animals infected with virus were transplanted with DMEM/F12
alone at T9 of the spinal cord. For further details, refer to Carbajal
et al. (2011).834 Stem Cell Reports j Vol. 2 j 825–837 j June 3, 2014 j ª2014 The AuthorIVIS Imaging
Bioluminescence imaging (BLI) of firefly luciferase (FLUC)-express-
ing hNPCs was performed daily posttransplantation for 8 days, at
which point no bioluminescent signal was observed. Mice were
anesthetized by isofluorine gas inhalation via nose-comb and
remained under sedation during imaging. Ten minutes prior to
image acquisition, mice were injected intraperitoneally with
250 mg/kg body weight of D-luciferin in PBS. Photons emitted
from transplanted cells were used to construct a pseudocolor image
of bioluminescent intensity that was overlaid onto a gray-scale
photograph of the mice.
Histopathology and Immunohistochemistry
Animals were sacrificed by inhalation of an overdose of isoflurane
(WesternMedical Supplies) and perfusedwith PBS by cardiac perfu-
sion. The spinal cords were harvested and fixed in 4% paraformal-
dehyde overnight before being embedded in resin or in OCT
medium for cryosectioning as previously described (Totoiu et al.,
2004). Cryosections of spinal cords were stained with Harrison
hematoxylin and eosin (H&E) to visualize cellular inflammation
or with luxol fast blue (LFB) and counterstainedwithH&E to assess
the severity of demyelination. Scoring of resin-embedded sections
was performed using a previously described method (Glass et al.,
2004; Lane et al., 2000). In brief, the demyelination scale is as fol-
lows: 0, no demyelination; 1, mild inflammation accompanied by
loss of myelin integrity; 2, moderate inflammationwith increasing
myelin damage; 3, numerous inflammatory lesions accompanied
by significant increase in myelin stripping; and 4, intense areas
of inflammation accompanied by numerous phagocytic cells en-
gulfing myelin debris. All slides were blinded and read indepen-
dently by two investigators. For immunohistochemical staining,
cryosections (8 mm) were incubated at 4C overnight with combi-
nations of the following primary antibodies: STEM121 antibody
(1:200 dilution; Stemcells) for detection of human NPCs, anti-
iBA-1 antibody (1:400 dilution; Wako) for detection of activated
macrophages/microglia, and anti-CD3 (1:200 dilution; BD Phar-
Mingen) as a pan-T cell marker. A biotinylated secondary antibody
(1:400 dilution; Vector Laboratories) and the ABC Elite staining
system (Vector Laboratories) were used to visualize the primary
antibodies in accordance with the manufacturer’s instructions.
Diaminobenzidine (DAB) was used as a chromogen.
Immunofluorescence
Cryosections (8 mm) were washed in PBS three times and then
blocked with PBS with 0.03% Triton X-100 and 10% normal goat
serum (NGS; Jackson ImmunoResearch) for 1 hr at room tempera-
ture. Rat anti-mouse CD3 and anti-mouse IBA-1 (1:400 dilution,
Wako) (1:200 dilution; BD PharMingen) was applied to samples
and incubated overnight at 4C. Samples were washed again in
PBS three times, and then Alexa-Fluor-conjugated secondary anti-
body (goat anti-rat Alexa 488; 1:500 in PBS; Invitrogen) was
applied for 1 hr at room temperature. All slides were then washed
in PBS and coverslip mounted using Vectashield Mounting Me-
dium with DAPI (Vector Laboratories). Negative controls were
incubated in PBS instead of primary antibodies. The number of im-
munopositive cells for anti-mouse CD3 and anti-IBA-1 staining
was determined by using the ImageJ cell counter.s
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For EM analysis of spinal cords, mice were sacrificed and under-
went cardiac perfusion with 0.1 M cacodylate buffer containing
2%paraformaldehyde/2%glutaraldehyde. Serial ultrathin sections
of spinal cords embedded in Epon epoxy resin were stained with
uranyl acetate-lead citrate and analyzed as previously described
(Liu et al., 2001). Images at 1,2003 magnification were analyzed
for g-ratio using ImageJ software. In adult animals there is a
relationship between axon circumference and myelin sheath
thickness (number of lamellae) expressed by the g-ratio (axon
diameter/total fiber diameter); in remyelination, this relationship
changes such that myelin sheaths are abnormally thin for the
axons they surround. An abnormally thin myelin sheath, relative
to axonal diameter, was used as the criterion for oligodendrocyte
remyelination. Absence of a myelin sheath was used as the crite-
rion for demyelination. For most axons, two measurements were
conducted with a minimum of 500 axons analyzed per experi-
mental group. In all cases, slides were blinded and read indepen-
dently by three investigators.
Isolation of Lymphocytes from Spinal Cord
Cells were isolated from the spinal cords of experimental mice as
previously described (Lane et al., 2000). Single-cell suspensions
were centrifuged for 30 min at 1,200 3 g at 4C over a discontin-
uous Percoll gradient and then Percoll and lipid layers were
removed. Isolated cells were filtered, washed with 20 ml DMEM,
centrifuged at 1,000 3 g at 4C, counted, and prepared for flow
cytometry (see below). Cells isolated from spleenswere used as pos-
itive controls.
Flow Cytometry
Lymphocytes isolated from the spinal cord were immunopheno-
typed with fluorescent antibodies (1:200) for the following cell-
surface markers: fluorescein isothiocyanate (FITC)-conjugated
CD4 (GK1.5; BD Biosciences), PE-Cy7-conjugated CD8 (Ly-2; BD
Biosciences), antigen-presenting cell (APC)-conjugated CD25
(PC61; BD Biosciences), APC-conjugated CD45 (30-F11;
eBioscience), FITC-conjugated F4/80 (Ci-A3-1; Serotech), and
Alexa Fluor 647-conjugated FOXP3 (FJK-16 s; eBioscience). PE-con-
jugated I-Ab/M133–147 tetramers and PE-conjugated Db/S510–
518 (8 mg/ml; obtained from the National Institutes of Health/
National Institute of Allergy and Infectious Diseases MHC
Tetramer Core Facility) were used to stain viral-specific CD4
T cells and viral-specific CD8 T cells, respectively. Appropriate
isotype controls were used for each antibody. Cells were run on a
LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo
software (Tree Star). All cells for flow cytometry were blocked
with anti-mouse CD16/32 (Mouse Fc Block; 1:200; BD Biosciences)
for 20 min at 4C.
Treatment of Mice with CD25 Antibody
JHMV-infected mice were intraperitoneally (i.p.) treated with
150 mg of a blocking antibody specific for mouse CD25 (rat anti-
mouse CD25, clone PC61.5) or control rat immunoglobulin G
(Sigma) in 100 ml sterile saline at days 2, 0, and 2 posttransplan-
tation. Spinal cords were removed from hNPC-transplanted and
control mice at day 10 posttransplantation, and the presence ofSteCD4+CD25+FoxP3+ cells (Tregs) was assayed by flow cytometry
(see above). Draining cervical lymph nodes were analyzed 9 days
after antibody administration to determine efficacy of anti-CD25
treatment.T Cell Proliferation Assays
Splenocytes were isolated from JHMV (DM strain)-infected mice
and pulsed with the CD4+ T-cell-specific immunodominant
M133–147 peptide for 24 hr. T cells were purified from the treated
splenocytes by using the Pan T Cell Isolation Kit II (Miltenyi
Biotec) and labeled with eFluor 670 (eBiosciences). T cells (1 3
105 cells/well) in 200 ml complete medium (RPMI-1640 [Life Tech-
nologies] supplemented with 13GlutaMAX-1 [Life Technologies],
13 nonessential amino acids [Life Technologies], 100 U/ml
penicillin [Life Technologies], 100 mg/ml streptomycin [Life Tech-
nologies], 1 mM sodium pyruvate [Life Technologies], 55 mM
2-mercaptomethanol [Life Technologies], and 10% fetal bovine
serum [Atlanta Biologicals]) were plated in round-bottomed 96-
well plates (Corning) and incubated at 37C, 5% CO2, for 4 days
before being analyzed by flow cytometry. Concanavalin A
(2.5 mm/ml, Sigma-Aldrich) was used as a T cell proliferation stim-
ulant. For the TGF-b1 and TGF-b2 blocking experiments, anti-
TGF-b1 antibody ab64715 (0.5 mg/ml, Abcam) and anti-TGF-b2
antibody ab10850 (0.1 mg/ml, Abcam) were also included in the
cell-culture medium.ELISAs
Levels of mouse IFN-g, TNF-a, and IL-10 from stimulated T cells
isolated from draining cervical lymph nodes were determined
by ELISA using specific Mouse DuoSet in accordance with the
manufacturer’s specifications (R&D Systems). Human hepatocyte
growth factor (HGF), TGF-b1, and TGF-b2 production by cultured
hESCs and hNPCswas determined using humanQuantikine ELISA
Kits from R&D Systems in accordance with the manufacturer’s
specifications.qRT-PCR
The QuantiTect Reverse-Transcription Kit (QIAGEN) was used to
generate cDNAs from RNA collected from cell samples. TaqMan
gene expression probes were obtained for TGFB1, TGFB2, and
HGF from Life Technologies. qRT-PCR was performed on the
cDNAs using the TaqMan gene expression master mix (Life
Technologies) to quantify transcript levels in a BioRad C1000 ther-
mal cycler (Bio-Rad). Values were normalized to internal GAPDH
levels and shown as a fold change of ESC expression using DDCt
calculations.
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